For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Cagrilintide is a once-weekly injectable amylin analogue developed by Novo Nordisk that activates both amylin and calcitonin receptors to produce satiety and reduce food intake. In Phase 3 REDEFINE 1 (n=3,417), cagrilintide combined with semaglutide achieved 20.4% mean body weight loss at 68 weeks versus 3.0% with placebo. Monotherapy produced 11.8% weight loss in the same trial. An NDA for the CagriSema combination was filed with the FDA in December 2025.
Cagrilintide is the most extensively studied amylin-targeting compound ever developed, with published Phase 3 data from two large RCTs and a filed New Drug Application. This is not a preclinical compound with speculative human extrapolation: the mechanism, dose-response, safety, and 68-week efficacy are established in controlled human trials enrolling more than 4,600 participants.
However, context prevents reading the headline figure as the whole story. The 20.4% mean body weight loss at 68 weeks is the combination product (CagriSema), not cagrilintide alone. Cagrilintide monotherapy in the same trial achieved 11.8%, while semaglutide monotherapy achieved 14.9%. Cagrilintide adds approximately 5.5 percentage points when combined with semaglutide, but does not outperform semaglutide when given alone. The combination did not demonstrate noninferiority to tirzepatide 15 mg in REDEFINE 4, an open-label head-to-head trial.
Regulatory status is a hard constraint. As of March 2026, the FDA has explicitly stated that cagrilintide cannot be used in compounding under federal law. Any product sold by research chemical vendors as cagrilintide exists outside any regulatory framework. The NDA decision is expected around October 2026.
Amylin is a 37-amino-acid peptide co-secreted with insulin by pancreatic beta cells in response to meals. It functions as a satiety signal through amylin receptors in the area postrema and nucleus of the solitary tract in the brainstem, reducing meal size, slowing gastric emptying, and suppressing postprandial glucagon secretion. Amylin deficiency accompanies beta cell failure in both type 1 and type 2 diabetes.
The first approved amylin analogue, pramlintide (Symlin), gained FDA approval in 2005 as an adjunct to insulin for diabetes. Its limitation is pharmacokinetic: a short half-life requires three-times-daily subcutaneous injection at mealtimes. Pramlintide produces modest weight loss and improved glycemic control but is rarely used in practice due to injection burden.
Cagrilintide was developed by Novo Nordisk through a structure-activity relationship program reported in a 2021 Journal of Medicinal Chemistry paper (Larsen et al.). The key design challenges were amylin's propensity to form amyloid fibrils and its short half-life. Cagrilintide resolves both through multiple amino acid substitutions, a C-terminal amide, and N-terminal fatty acid acylation, extending the half-life to approximately 160 to 195 hours, enabling once-weekly dosing. The result is a Dual Amylin and Calcitonin Receptor Agonist (DACRA) that activates amylin receptor subtypes and the calcitonin receptor itself.
Clinical development has progressed rapidly. A Phase 1b trial (2018 to 2019) established safety and pharmacokinetics of cagrilintide combined with semaglutide. A Phase 2 dose-finding trial in 706 adults (2019 to 2021) established the dose-response and the 2.4 mg once-weekly dose for Phase 3. The REDEFINE Phase 3 program enrolled approximately 4,600 adults across REDEFINE 1 (non-diabetic) and REDEFINE 2 (T2D). An NDA for CagriSema (the fixed-dose combination) was filed December 18, 2025.
Cagrilintide is classified as a Dual Amylin and Calcitonin Receptor Agonist (DACRA). Amylin receptors are not standalone proteins: they are heterodimers formed by the calcitonin receptor (CTR) combined with receptor-activity modifying proteins (RAMP1, RAMP2, or RAMP3), generating three subtypes designated AMY1R, AMY2R, and AMY3R. Cagrilintide binds all three amylin receptor subtypes and the CTR itself, a non-selective receptor engagement that distinguishes it from purely amylin-selective candidates.
In the brain, the primary sites of amylin receptor action are the area postrema (AP) and the nucleus of the solitary tract (NTS) in the hindbrain, regions where the blood-brain barrier is incomplete and circulating peptides can access neurons. Cagrilintide activation here reduces meal size and food intake through a satiety signal mechanistically distinct from GLP-1 receptor signaling. Receptors in the hypothalamus, ventral tegmental area, and laterodorsal tegmental nucleus suggest engagement of both homeostatic and hedonic (reward-based) food intake regulation.
Peripherally, cagrilintide slows gastric emptying through vagal pathways and suppresses postprandial glucagon secretion, extending the satiety window after meals and blunting postprandial glucose excursions. The calcitonin receptor activation adds calcium homeostasis and bone metabolic effects that are independent of the appetite-suppressing mechanism and under active clinical investigation.
The mechanistic basis for additive weight loss when cagrilintide is combined with semaglutide is proposed to be complementary neuroanatomy: semaglutide acts through GLP-1 receptors in the hypothalamic arcuate nucleus and area postrema, while cagrilintide engages amylin/RAMP receptor complexes in overlapping but distinct brainstem circuits. Dual engagement of different receptor populations with different downstream signaling pathways appears to produce additive appetite suppression, consistent with the REDEFINE 1 combination superiority over either monotherapy.
Cryo-EM structural studies published in Nature Communications (2025) characterized cagrilintide bound to all four receptor configurations (AMY1R, AMY2R, AMY3R, and CTR), finding an amylin-like binding mode that induces distinct conformational dynamics compared with native amylin or salmon calcitonin. Preclinical RAMP1/3 knockout studies (eBioMedicine, 2025) confirmed that AMY1R and AMY3R are required for the full weight-lowering effect.
REDEFINE 1 enrolled 3,417 adults without diabetes who had obesity or overweight with at least one comorbidity. CagriSema produced a mean body weight reduction of 20.4% versus 3.0% with placebo at 68 weeks, an estimated difference of 17.3 percentage points (95% CI: 18.1 to 16.6; p less than 0.001). Using the trial product estimand (all-treated scenario), the figure was 23%. Active comparators: semaglutide alone achieved 14.9% and cagrilintide alone achieved 11.8%, establishing additive benefit.
Responder analyses showed significantly higher proportions of CagriSema participants achieving 20% or more, 25% or more, and 30% or more weight loss compared with placebo (p less than 0.001). Quality of life scores (IWQOL-Lite-CT and SF-36 physical function) improved significantly versus placebo. Gastrointestinal adverse events were the primary tolerability limitation, affecting 79.6% of CagriSema participants versus 39.9% with placebo, mainly transient and mild-to-moderate.
REDEFINE 2 in 1,206 T2D adults showed 13.7% mean weight loss with CagriSema versus 3.4% with placebo. Glycemic endpoints including HbA1c were significantly improved.
REDEFINE 4 (n=809, open-label, 84 weeks), comparing CagriSema to tirzepatide 15 mg, showed 23% weight loss with CagriSema but failed to meet the primary noninferiority endpoint against tirzepatide. The trial's open-label design introduces bias considerations but the result establishes that superiority over tirzepatide was not demonstrated.
CagriSema has the most complete Phase 3 dataset of any first-in-class amylin combination product ever studied. The 20.4% weight loss (ITT) positions it above semaglutide monotherapy but without demonstrated superiority over tirzepatide. The FDA decision expected approximately October 2026 will determine prescribability. The clinical value proposition rests on additive efficacy versus GLP-1 monotherapy and potentially better vomiting tolerability, not superiority across all comparators.
In the Phase 2 dose-finding trial, cagrilintide produced dose-dependent weight loss across all doses: mean reductions of 6.0% to 10.8% (6.4 to 11.5 kg) versus 3.0% with placebo (estimated treatment difference range: 3.0% to 7.8%; p less than 0.001 for all). At 4.5 mg, weight loss (10.8%, 11.5 kg) was significantly greater than with liraglutide 3.0 mg (9.0%, 9.6 kg; estimated treatment difference 1.8%; p=0.03). Permanent treatment discontinuation was 10% overall, mostly from adverse events.
The REDEFINE 1 monotherapy subanalysis (n=302 cagrilintide 2.4 mg arm, 68 weeks) showed 11.8% mean weight loss versus 2.3% with placebo. Mean absolute weight reduction was 12.5 kg versus 2.5 kg. Approximately 31.6% achieved 15% or more weight loss compared with 4.7% with placebo. Based on these first Phase 3 monotherapy data, Novo Nordisk announced the Phase 3 RENEW monotherapy program, initiated Q4 2025.
Critical comparison: in the same REDEFINE 1 trial, semaglutide 2.4 mg monotherapy achieved 14.9% weight loss. Cagrilintide monotherapy at 2.4 mg (11.8%) is therefore statistically and clinically below semaglutide monotherapy at the same once-weekly schedule in direct trial comparison. This is the honest accounting of where cagrilintide stands as a monotherapy.
Cagrilintide monotherapy produces clinically meaningful weight loss, with Phase 2 and Phase 3 subanalysis data consistently showing 10% to 12% mean reduction. However, it does not outperform semaglutide in direct comparison. Its monotherapy value case rests on the tolerability argument, specifically lower vomiting rates for patients who cannot tolerate GLP-1 agonists, and on providing a mechanistically distinct option for patients with GLP-1 resistance or intolerance. Phase 3 RENEW will determine whether regulatory approval for monotherapy is pursued separately.
In the Phase 2 T2D trial (n=92, 32 weeks), CagriSema reduced HbA1c by 2.2 percentage points and fasting blood glucose by 3.3 mmol/L, with 15.6% mean body weight loss from baseline. CagriSema showed significantly greater HbA1c and weight reduction compared with either cagrilintide or semaglutide alone. The trial was active-controlled (not placebo-controlled) and enrolled 92 participants, limiting statistical power.
In REDEFINE 2 (n=1,206, 68 weeks), CagriSema achieved 13.7% mean weight loss versus 3.4% with placebo. HbA1c reductions and other glycemic control measures showed significant improvement. The 13.7% weight loss in the T2D population is approximately 6 percentage points below the 20.4% achieved in the non-diabetic REDEFINE 1 population, consistent with the established pattern that metabolic disease attenuates pharmacological weight loss.
The independent glycemic contribution of cagrilintide versus semaglutide in the combination cannot be fully separated from the Phase 3 design. Calcitonin receptor activation may contribute independently to glucose regulation in diabetic conditions, but this is not definitively quantified in the published data.
CagriSema produces meaningful but attenuated weight loss in T2D and significant HbA1c improvements. The approved semaglutide component contributes known glycemic efficacy; the incremental glycemic contribution of cagrilintide is biologically plausible but not independently isolated. REDEFINE 2 data support the T2D indication in the NDA filing.
In the Phase 2 trial, gastrointestinal adverse events with cagrilintide affected 41% to 63% versus 32% with placebo. Nausea was 20% to 47% across doses; the 2.4 mg dose is at the lower end of this range. Vomiting rates were lower with cagrilintide than with comparator GLP-1 agents at comparable weight loss in meta-analytic summaries.
The meta-analysis (Alfaris et al., 2023) pooled data showing lower odds ratios for nausea, vomiting, and diarrhea with cagrilintide compared with semaglutide or liraglutide across published systematic reviews of each class. Cagrilintide does not act through GLP-1 receptors; nausea and vomiting mediated by GLP-1 receptor activation in the area postrema are a different and partly separable signal from amylin-mediated satiety effects.
In REDEFINE 1, overall gastrointestinal adverse events affected 79.6% of the CagriSema group, driven substantially by the semaglutide component. The low discontinuation rate in REDEFINE, where participants could remain at submaximal doses, provides indirect evidence that tolerability is manageable when dose titration is flexible rather than protocol-mandated.
The tolerability differentiation hypothesis for cagrilintide monotherapy versus GLP-1 agonists has not been directly tested in a population selected for prior GLP-1 intolerance.
The case that cagrilintide produces less vomiting than semaglutide at comparable efficacy is directionally supported by meta-analytic comparisons and mechanistic logic, but has not been tested in a tolerability-enriched head-to-head trial. For patients who have discontinued GLP-1 therapy due to vomiting, cagrilintide monotherapy (once approved) represents a mechanistically distinct pathway, but clinical confirmation is needed.
This use case is in active investigation with no human outcome data available. The scientific rationale: weight loss from any cause including pharmacological weight loss with GLP-1 agonists is associated with reductions in bone mineral density, a clinically meaningful concern particularly in postmenopausal women and older adults already at elevated fracture risk. The calcitonin receptor, which cagrilintide activates, plays a central role in calcium homeostasis and bone metabolism, inhibiting osteoclast activity and potentially preserving bone density.
The hypothesis under investigation is that cagrilintide's CTR activation may partially or fully offset the bone density loss associated with significant pharmacological weight reduction, a property that GLP-1 agonists do not share. If confirmed in NCT07010432, this would differentiate cagrilintide-containing therapy from GLP-1 monotherapy in a clinically important way.
No outcome data are available. The calcitonin connection also raises a monitoring consideration: products with calcitonin receptor activity carry a historical association with possible malignancy risk (observed with nasal calcitonin for osteoporosis), and Novo Nordisk explicitly designed cagrilintide to resemble pramlintide more than salmon calcitonin at the receptor level. Toxicological studies did not reveal major malignancy signals in Phase 2 or Phase 3, but trial durations are insufficient to characterize long-term cancer risk.
Mechanistically motivated hypothesis with active Phase 3-adjacent clinical investigation and zero human outcome data. The potential bone-sparing effect during weight loss would be a clinically meaningful differentiator if confirmed. No data should be taken from mechanism alone. Results from NCT07010432 are expected during 2026 to 2027 and are worth following closely.
Clinical doses up to 4.5mg studied for obesity.
Cagrilintide pharmacokinetics are among the best characterized of any peptide reviewed on this site. Half-life 160 to 195 hours; dose-proportional exposure across 0.16 to 4.5 mg; no PK interaction with semaglutide; steady state in approximately 5 weeks. The 16-week escalation is clinically essential, not optional: skipping escalation dramatically increases GI adverse events. The FDA explicitly prohibits cagrilintide compounding under current federal law. Any product labeled cagrilintide sold by research chemical vendors exists outside any regulatory framework and has not been found safe and effective.
Among GLP-1 class obesity treatments on this site, semaglutide and tirzepatide have full FDA approval; retatrutide has Phase 2 data with Phase 3 ongoing. Cagrilintide occupies a distinct mechanistic niche as an amylin/calcitonin receptor agonist and is most potent as a combination partner with semaglutide rather than as a standalone. Its predecessor, pramlintide, remains the only approved amylin analogue but is rarely used due to TID injection requirements. Among all compounds in this series, cagrilintide has the most Phase 3 data of any investigational peptide reviewed, making it unusually close to the Tier 1 boundary defined by FDA approval.
The safety profile of cagrilintide is defined by four main categories across Phase 1b, Phase 2, and Phase 3 studies.
Gastrointestinal adverse events are the dominant signal. In Phase 2 (Enebo et al., 2021), 41% to 63% of cagrilintide-treated participants reported gastrointestinal adverse events versus 32% with placebo. Nausea was most common: 20% to 47% versus 18% with placebo, dose-dependent. In REDEFINE 1 (Garvey et al., 2025), gastrointestinal adverse events affected 79.6% of CagriSema participants versus 39.9% with placebo; these were described as mainly transient and mild-to-moderate. Meta-analytic comparisons across incretin-based therapies suggest cagrilintide produces lower vomiting rates than semaglutide or liraglutide at comparable efficacy. Standard management is 16-week gradual dose escalation. The low discontinuation rate in REDEFINE, where participants could choose submaximal dosing, suggests tolerability is manageable with dosing flexibility.
Injection site reactions occurred at higher rates than placebo across trials. They were generally mild and transient. No severe systemic allergic reactions were reported in Phase 2 or Phase 3 data.
Anti-drug antibodies developed in 46% to 73% of participants by week 26 in Phase 2 studies, with incidence increasing at higher doses and longer exposure. Critically, these antibodies did not appear to reduce efficacy, and no severe allergic reactions associated with antibody formation were observed. Long-term antibody implications remain an open question requiring post-marketing data.
The calcitonin receptor component raises two distinct considerations. First, calcitonin-containing products carry a historical association with possible increased malignancy risk (observed with nasal calcitonin for osteoporosis). Novo Nordisk designed cagrilintide to resemble pramlintide more than salmon calcitonin at the receptor level, and toxicological studies did not reveal major malignancy signals. No excess malignancy was reported in Phase 3, but trial durations (68 weeks) are insufficient to characterize cancer risk. Post-marketing surveillance will be required. Second, cagrilintide's CTR activation affects bone metabolism, the subject of a dedicated active clinical trial (NCT07010432) in postmenopausal women with obesity. No clinical bone outcome data are yet available.
Clinical guidance analogous to GLP-1 agonist contraindications has been applied to cagrilintide by extrapolation: avoid in personal or family history of medullary thyroid carcinoma and in multiple endocrine neoplasia syndrome type 2 (MEN2), due to CTR overlap. These are precautionary, not established from Phase 3 cagrilintide data.
Cardiovascular outcomes data do not yet exist. REDEFINE 3, a Phase 3 cardiovascular outcomes trial, was ongoing as of March 2026. The Phase 3 safety data showed no unexpected cardiovascular signals, but formal MACE outcomes require the outcomes trial.
Cagrilintide is the most extensively studied amylin analogue ever developed, with Phase 3 RCT data published in the NEJM, an NDA filed, and an FDA decision expected in late 2026. The evidence base is real, methodologically strong, and arrives with clinical context that most research peptides on this site lack entirely.
The honest weight loss accounting: CagriSema combination achieved 20.4% mean weight loss at 68 weeks in REDEFINE 1. Cagrilintide alone achieved 11.8% in the same trial. Semaglutide alone achieved 14.9%. Cagrilintide adds approximately 5.5 percentage points when combined with semaglutide, which is the primary clinical case for the combination. The combination did not demonstrate noninferiority to tirzepatide 15 mg in REDEFINE 4.
The open questions are not trivial: cardiovascular outcomes, long-term cancer risk from CTR activation, bone effects at multi-year exposure, and whether anti-drug antibody titers have clinical consequences beyond week 26. These will require post-approval surveillance data.
For anyone considering cagrilintide outside a regulated clinical context: it cannot legally be compounded in the US under current law. Any vendor selling it is operating outside any regulatory framework. If the FDA approves CagriSema in late 2026, there will be a legitimate pathway to access it through prescription. Until then, the Phase 3 data answer the question of whether it works in humans. The regulatory process exists to answer whether it can be prescribed safely.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use